Axela, Inc. Launches dotLab(TM) System in Europe

01/04/2008 - 16:45

Axela Inc., a recognized innovator in protein interaction
technology, announced the introduction of the dotLab(TM) System in
Europe at Analytica 2008, being held in Munich, Germany, April 1-4,
2008. The system, successfully introduced in North America in 2007, is
now being used by life scientists in the academic, pharmaceutical,
biotechnology and clinical research fields to exploit interactions
between a protein target and other biomolecules.

Chosen by Frost and Sullivan as the Protein Assay Product of the
Year for 2007, the dotLab System brings real-time monitoring to the
study of protein interactions, expression, immunoassay development,
and routine quantitation. This eliminates the time and cost of
platform transitions associated with conventional approaches.

The presentation at Analytica, Understanding Interactions Enables
Real-Time Immunoassays, will be given by Paul Smith, VP Research
Markets in the Innovations and Technology Forum on April 3, 2008, Hall
A3, 384/I, 13:00 - 13:30. The dotLab system will be on display in Hall
A3, Booth 276.

"We are excited to have achieved this milestone in Axela´s
corporate growth," says Rocky Ganske, Axela President and CEO.
"Existing users quickly demonstrated how understanding interactions
can improve protein detection and quantitation. Simultaneously
measuring low and high abundance proteins and interrogating complexes
directly in biological samples enables significant new applications."

Axela´s European Sales and Support Office will be located in
Bemmel, The Netherlands and managed by TouchDown Biomarketing B.V.
This highly experienced team provides local scientific and technical
support and is backed by extensive consumable and reagent distribution
capability.

About Axela, Inc.

Axela has developed a proprietary technology for real-time protein
detection, characterization, and monitoring directly in biological
samples. The company´s products provide simple tools and reagents to
life science and clinical researchers to study interactions, expand
the utility of traditional immunoassays and access novel categories of
diagnostic markers. Participating in the research market provides
unique access to novel discoveries that form the basis of a growing
content pipeline for future multiplex diagnostic offerings. Axela is a
privately-held company with operations in Toronto and California whose
major investor is VenGrowth Private Equity Partners Inc., one of
Canada´s premier private equity managers.